A few questions, folded into your pocket
Dear reader,
An appointment isn't a memory contest. I'd rather bring a few questions and leave room for answers than try to remember every study I've read. Here are the five I'd take into a conversation about semaglutide.
You can start with whichever feels most useful. The list can't decide whether treatment fits you; that's part of the conversation with a clinician who can consider your history.
1. What are we trying to change?
“Is the main goal blood sugar, weight or a particular health risk?” I'd ask for the answer in everyday words, followed by how it will be checked. It gives the next appointment something clear to return to.
The diabetes trial and the heart-outcome trial in people without diabetes asked different questions. The latter, SELECT, involved adults aged 45 or older with established cardiovascular disease and a body mass index (BMI) of at least 27, without diabetes. A good result can be real and still answer a different question from yours.
2. What in my history changes the decision?
I'd make room for current medicines, past health problems and pregnancy plans. The Wegovy (semaglutide injection and tablets) label identifies several concerns, including pancreas or gallbladder problems, severe stomach problems, diabetic eye disease and low blood sugar with certain other diabetes medicines.
It also rules out use with a personal or family history of medullary thyroid cancer, MEN 2—an inherited condition linked to certain tumors—or a previous serious allergic reaction to semaglutide or its ingredients. Planned procedures involving anesthesia belong in the discussion too. Those are label concerns, rather than a prediction about what any one clinic will ask.
3. Which exact product do you mean?
“What is its name, which form is it, and what is it approved for?” The labels for Wegovy (semaglutide injection and tablets) and Ozempic (semaglutide injection) describe different approved uses. A shared ingredient doesn't make every product the same. Results from the study medicines don't establish that a compounded preparation will have equivalent safety or effectiveness.
If a compounded preparation comes up, I'd ask why it's being considered for this situation. The FDA explains that compounded medicines aren't FDA-approved. The dose letter also explains why a tablet number can't be compared directly with an injection number.
4. Who can I reach between appointments?
I'd ask what follow-up is planned and which symptoms need urgent attention. The label includes serious safety warnings. A general website can't judge a symptom or tell you whether it's safe to wait.
“Who do I contact if the medicine is hard to tolerate?” is worth writing down. The answer is more useful if it includes how to reach that person.
5. What happens if treatment ends?
In the STEP 1 extension, adults previously assigned semaglutide regained substantial weight, on average, over the year after treatment and lifestyle support stopped. They had obesity, or overweight with a related health condition, without diabetes. I'd ask about ongoing care early, without treating that finding as a decision to stop or continue.
P.S. “Could we write down the goal, the follow-up and why we might change course?” Those answers give this page a job after the appointment.